Michael J. Pishvaian
About
Michael J. Pishvaian is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Michael J. Pishvaian has authored 216 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Oncology, 70 papers in Pulmonary and Respiratory Medicine and 70 papers in Cancer Research. Recurrent topics in Michael J. Pishvaian's work include Pancreatic and Hepatic Oncology Research (100 papers), Cancer Genomics and Diagnostics (62 papers) and Colorectal Cancer Treatments and Studies (34 papers). Michael J. Pishvaian is often cited by papers focused on Pancreatic and Hepatic Oncology Research (100 papers), Cancer Genomics and Diagnostics (62 papers) and Colorectal Cancer Treatments and Studies (34 papers). Michael J. Pishvaian collaborates with scholars based in United States, Canada and Japan. Michael J. Pishvaian's co-authors include Jonathan R. Brody, John L. Marshall, Stephen W. Byers, Aline Charabaty, Aiwu Ruth He, Jimmy J. Hwang, Joanne Xiu, Subha Madhavan, Andrew Hendifar and Patrick A. Ott and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Michael J. Pishvaian
200 papers receiving 5.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michael J. Pishvaian United States | 40 | 3.8k | 1.9k | 1.5k | 1.1k | 831 | 216 | 5.8k | ||
| Young Kwang Chae United States | 40 | 3.1k 0.8× | 2.6k 1.3× | 1.7k 1.2× | 1.9k 1.7× | 820 1.0× | 274 | 6.4k | ||
| Shubham Pant United States | 32 | 2.7k 0.7× | 1.5k 0.7× | 1.2k 0.8× | 956 0.9× | 701 0.8× | 279 | 4.5k | ||
| E. Gabriela Chiorean United States | 42 | 4.7k 1.2× | 2.1k 1.1× | 1.7k 1.1× | 1.5k 1.4× | 1.7k 2.1× | 209 | 7.1k | ||
| Matthew H. Taylor United States | 36 | 3.5k 0.9× | 1.4k 0.7× | 687 0.5× | 1.6k 1.4× | 1.1k 1.4× | 173 | 6.4k | ||
| Andrew H. Ko United States | 35 | 3.8k 1.0× | 1.4k 0.7× | 1.7k 1.1× | 963 0.9× | 551 0.7× | 150 | 4.9k | ||
| Ignacio Garrido‐Laguna United States | 32 | 3.1k 0.8× | 1.8k 0.9× | 1.5k 1.0× | 1.1k 1.0× | 493 0.6× | 160 | 4.9k | ||
| Kyriakos P. Papadopoulos United States | 47 | 3.8k 1.0× | 4.3k 2.2× | 1.2k 0.8× | 1.5k 1.3× | 1.4k 1.7× | 324 | 8.1k | ||
| Mark N. Stein United States | 40 | 2.5k 0.7× | 2.3k 1.2× | 1.3k 0.9× | 2.1k 1.9× | 880 1.1× | 243 | 5.8k | ||
| Helen Mackay Canada | 41 | 2.9k 0.8× | 2.9k 1.5× | 1.3k 0.9× | 1.2k 1.1× | 576 0.7× | 185 | 7.1k | ||
| Daniele Generali Italy | 42 | 3.1k 0.8× | 2.5k 1.3× | 2.1k 1.4× | 1.7k 1.5× | 475 0.6× | 232 | 6.2k |
Countries citing papers authored by Michael J. Pishvaian
Since
Specialization
Citations
This map shows the geographic impact of Michael J. Pishvaian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Pishvaian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Pishvaian more than expected).
Fields of papers citing papers by Michael J. Pishvaian
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael J. Pishvaian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Pishvaian. The network helps show where Michael J. Pishvaian may publish in the future.
Co-authorship network of co-authors of Michael J. Pishvaian
This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Pishvaian. A scholar is included among the top collaborators of Michael J. Pishvaian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Pishvaian. Michael J. Pishvaian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ardalan, Bach, Yasmine Baca, Andrew Hinton, et al.. (2025). Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma. Clinical Cancer Research. 31(6). 1082–1090.
2.
Boland, Patrick M., Heinz‐Josef Lenz, Kristen K. Ciombor, et al.. (2024). A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer. Investigational New Drugs. 43(1). 60–68.
3.
Pishvaian, Michael J., Amer H. Zureikat, Charles D. Lopez, et al.. (2023). Abstract CT084: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following Induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC) - phase III trial interim analysis. Cancer Research. 83(8_Supplement). CT084–CT084.
4.
Goodman, Karyn A., Michael J. Pishvaian, Charles D. Lopez, et al.. (2023). Toxicity and efficacy of stereotactic body radiation therapy vs. intensity-modulated radiation therapy for the treatment of locally advanced pancreatic cancer in a phase 3 trial.. Journal of Clinical Oncology. 41(4_suppl). 713–713.
5.
Pishvaian, Michael J., Charles D. Lopez, Emmanuel E. Zervos, et al.. (2023). LBA-1 The Phase III Study: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC). Annals of Oncology. 34. S178–S178.
6.
Armstrong, Samantha, Hongkun Wang, Marion L. Hartley, et al.. (2021). A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies. Cancer Medicine. 10(6). 1944–1954.
7.
Pishvaian, Michael J., Hongkun Wang, Aiwu Ruth He, et al.. (2020). A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research. 26(19). 5092–5101.
8.
Schultz, Christopher W., Aditi Jain, Austin Goetz, et al.. (2019). Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Molecular Cancer Research. 17(10). 2029–2041.
9.
Tesfaye, Anteneh, Hongkun Wang, Marion L. Hartley, et al.. (2019). A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. SHILAP Revista de lepidopterología. 5(1). 12–21.
10.
Segal, Neil H., Aiwu Ruth He, Toshihiko Doi, et al.. (2018). Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Clinical Cancer Research. 24(8). 1816–1823.
11.
Pishvaian, Michael J., R Joseph Bender, Lola Rahib, et al.. (2018). Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Clinical Cancer Research. 24(20). 5018–5027.
12.
Bauer, Tyler M., et al.. (2018). Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure. SHILAP Revista de lepidopterología. 4(1). 81–87.
13.
Ott, Patrick A., Yung‐Jue Bang, Dominique Berton-Rigaud, et al.. (2018). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Obstetrical & Gynecological Survey. 73(1). 26–27.
14.
Jansen, Valerie M., Neil E. Bhola, Joshua A. Bauer, et al.. (2017). Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research. 77(9). 2488–2499.
15.
Ott, Patrick A., Yung‐Jue Bang, Dominique Berton-Rigaud, et al.. (2017). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Journal of Clinical Oncology. 35(22). 2535–2541.
16.
Chand, Saswati N., Mahsa Zarei, Matthew J. Schiewer, et al.. (2017). Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. Cancer Research. 77(18). 5011–5025.
17.
Subramaniam, Deepa S., Aiwu Ruth He, Jimmy Hwang, et al.. (2015). Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer. Current Cancer Drug Targets. 14(9). 775–793.
18.
Mikhail, Sameh, Lindsay M. Hannan, Michael J. Pishvaian, & Craig M. Kessler. (2015). Retrievable inferior vena cava filters in patients with cancer are safe but are they beneficial?. Medical Oncology. 32(6). 622–622.
19.
Díaz‐Cruz, Edgar S., Bhaskar Kallakury, Michael J. Pishvaian, et al.. (2012). The CDK4/6 Inhibitor PD0332991 Reverses Epithelial Dysplasia Associated with Abnormal Activation of the Cyclin-CDK-Rb Pathway. Cancer Prevention Research. 5(6). 810–821.
20.
Hwang, Jimmy J., John Kuruvilla, David S. Mendelson, et al.. (2010). Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma. Clinical Cancer Research. 16(15). 4038–4045.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Young Kwang Chae Breakdown of academic impact, for papers by Shubham Pant Breakdown of academic impact, for papers by E. Gabriela Chiorean Breakdown of academic impact, for papers by Matthew H. Taylor Breakdown of academic impact, for papers by Andrew H. Ko Breakdown of academic impact, for papers by Ignacio Garrido‐Laguna Breakdown of academic impact, for papers by Kyriakos P. Papadopoulos Breakdown of academic impact, for papers by Mark N. Stein Breakdown of academic impact, for papers by Helen Mackay Breakdown of academic impact, for papers by Daniele Generali